ArticleCancers2025

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Holger N Lode et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.